Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone (Q33400871)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

Dietger Niederwieser

13

object named as

Dietger Niederwieser

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Wolfram Pönisch

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marc Andrea

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ina Wagner

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Doreen Hammerschmidt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ute Kreibich

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andreas Schwarzer

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas Zehrfeld

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maik Schwarz

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cornelia Winkelmann

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sirak Petros

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anette Bachmann

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tom Lindner

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

13 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

138

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1405-1412

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Metabolism and mechanisms of action of bendamustine: rationales for combination therapies

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Management of complications in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Renal Failure in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

1 reference

https://api.crossref.org/works/10.1007/S00432-012-1212-4

21 January 2018

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal failure in multiple myeloma. Pathogenesis and prognostic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-012-1212-4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33400871&oldid=2195324821"